Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONY: Niraparib and Abiraterone Acetate Plus Prednisone for mHSPC With HRR Alterations in Hispanic/Latino and Non-Hispanic Black Patients
NCT06392841Phase 2Withdrawn
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib + abiraterone acetate in prostate cancer (PCa). Planned start Oct 2025; status: withdrawn.
02
Drugs
niraparib + abiraterone acetate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06392841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392841.